| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.00▼ | 6.04▼ | 6.05▼ | 6.02▼ | 6.28▼ |
| MA10 | 6.01▼ | 6.06▼ | 6.05▼ | 5.99▼ | 6.39▼ |
| MA20 | 6.04▼ | 6.05▼ | 6.00▼ | 6.38▼ | 5.80▲ |
| MA50 | 6.07▼ | 6.02▼ | 5.94▲ | 6.43▼ | 5.84▲ |
| MA100 | 6.06▼ | 5.95▲ | 6.25▼ | 5.77▲ | 4.16▲ |
| MA200 | 6.01▼ | 6.29▼ | 6.50▼ | 5.87▲ | 3.13▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.004▼ | -0.011▼ | -0.002▼ | -0.051▼ | -0.011▼ |
| RSI | 37.960▼ | 44.537▼ | 48.323▼ | 42.979▼ | 52.152▲ |
| STOCH | 29.734 | 51.002 | 60.571 | 35.072 | 43.030 |
| WILL %R | -78.378▼ | -78.378▼ | -78.378▼ | -76.002▼ | -70.667 |
| CCI | -72.939 | -136.131▼ | -80.922 | -46.025 | -40.363 |
|
Thursday, September 17, 2026 06:32 AM
Nuvation Bio (NUVB) stock rises as the FDA approves a label update for the company's cancer therapy Ibtrozi to include new mid-stage trial data. Read more here.
|
|
Wednesday, September 16, 2026 10:10 AM
Nuvation Bio (NYSE:NUVB) presented new subgroup analyses of IBTROZI (taletrectinib) at the 2026 World Conference on Lung Cancer. The data indicated durable and consistent efficacy in advanced ROS1+ ...
|
|
Monday, June 29, 2026 05:01 PM
Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/09/26 | 6.025 | 6.06 | 5.94 | 5.99 | 574,521 |
| 22/09/26 | 6.26 | 6.26 | 5.955 | 6.10 | 4,323,956 |
| 21/09/26 | 6.00 | 6.105 | 5.8596 | 6.07 | 3,021,939 |
| 18/09/26 | 6.15 | 6.18 | 5.82 | 5.85 | 4,289,173 |
| 17/09/26 | 5.96 | 6.16 | 5.92 | 6.07 | 5,735,250 |
| 16/09/26 | 5.80 | 5.82 | 5.655 | 5.78 | 2,779,908 |
| 15/09/26 | 5.90 | 5.91 | 5.63 | 5.80 | 7,052,295 |
| 14/09/26 | 5.90 | 6.135 | 5.77 | 5.94 | 9,979,187 |
| 11/09/26 | 6.36 | 6.39 | 5.95 | 6.07 | 4,317,657 |
| 10/09/26 | 6.44 | 6.45 | 6.17 | 6.28 | 7,973,526 |
|
|
||||
|
|
||||
|
|